Fluorine-18 prostate-specific membrane antigen (PSMA)-1007 PET/CT improves locoregional staging compared with MRI in patients undergoing surgery for intermediate and high-risk prostate cancer. PSMA ...
In a parallel randomised trial, O-(2-[18F]fluoroethyl)-L-tyrosine (FET)-PET led to comparable survival outcomes to contrast-enhanced T1-weighted (CE-T1) MRI for re-irradiation planning in patients ...
A combined PSMA-PET/MRI scanner better detected clinically significant prostate cancer in men on active surveillance. The addition of piflufolastat F18 (18 F-DCFPyL) prostate-specific membrane antigen ...
Whole-body diffusion-weighted MRI scans may be as effective as traditional PET-CT scans for staging cancer tumors in children and young adults without exposing patients to ionizing radiation, ...
A research team from IOCB Prague, working in collaboration with the University of Tübingen, Germany, and the Faculty of Science, Charles University, has developed a new type of contrast agent that can ...
Hypoxia, or insufficient oxygen supply, plays a critical role in solid tumor growth and treatment resistance. The tumor microenvironment influences both the aggressiveness of a tumor and its ability ...
A more refined approach to the precise removal of brain tumors is on the horizon. The long-anticipated advancement is made achievable through the adaptation of tumor imaging processes employing ...
The U.S. Food and Drug Administration cleared the Siemens Biograph mMR system, which is the first device able to conduct a PET scan and an MRI scan at the same time, according to an FDA news release.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results